Landmark Dutch appeal court decision reduces risk of third-party damages against pharma patentees
The appellate ruling overturns a recent lower court judgment which exposed life sciences IP plaintiffs to significant additional dangers from health insurer lawsuits
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.